Dietrich Wenderoth - Concepedia

Concepedia

Author

Dietrich Wenderoth

Procter & Gamble (United States)

Also Known As

D Wenderoth, D. Wenderoth, Dietrich H. Wenderoth, Dietrich Wenderoth

13

Publications

1.3K

Citations

9

H-Index

12

Concepts

All Affiliations

Procter & Gamble (United States)Procter & Gamble (United Kingdom)Oregon Health & Science University KU Leuven

DW

About

Dietrich Wenderoth is an author at Procter & Gamble (United States) specializing in medicine, osteoporosis, and bone health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	535
2	Orthopaedics	2	2	219
3	Clinical Trials	2	2	442
4	Obstetrics	1	1	29
5	Menopause	1	1	29

Dietrich Wenderoth

×

9

Publications

1.3K

Citations

9

H-Index

	Year	Citations
Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized Trial David M. Reid, Rodney Hughes, Roland Laan, Journal of Bone and Mineral Research	2000	590
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience☆☆This study was sponsored by Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Aventis Pharma, Bridgewater, New Jersey. O. H. Sørensen, G. Crawford, Hindrik Mulder, Bone Long-term EfficacyClinical TherapeuticGamble PharmaceuticalsClinical TrialsPharmacotherapy	2003	254
Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study Steven Boonen, Eric Orwoll, Dietrich Wenderoth, Journal of Bone and Mineral Research Bone DiseaseBone Turnover MarkersBone HealthMale OsteoporosisOnce-weekly Risedronate	2008	188
Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover Richard Eastell, R.A. Hannon, Dietrich Wenderoth, The Journal of Clinical Endocrinology & Metabolism	2011	87
Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial Michael Hooper, Peter R. Ebeling, Adam P. Roberts, Climacteric	2005	55
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years Michael R. McClung, Ana Balske, David E. Burgio, Osteoporosis International	2012	47
The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water Alan C. Perkins, Clive Wilson, M. Frier, International Journal of Pharmaceutics EsophagusRapid Esophageal TransitMinimal VolumesSurgeryMedicine	2001	33
Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study Steven Boonen, R Lorenc, Dietrich Wenderoth, Bone Bone DiseaseBone HealthOrthopaedicsExtension StudyPlacebo-controlled Study	2012	31
Risedronate prevents bone loss in early postmenopausal women. Peter R. Ebeling, Anthony Roberts, Michael C dʼEmden, Queensland's institutional digital repository (The University of Queensland) Bone DiseaseBone HealthGynecologySkeletal BiologyEarly Postmenopausal Women	1999	29

Page 1